Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given an average recommendation of “Buy” by the ten brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $15.80.
Several brokerages have issued reports on KPTI. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Royal Bank of Canada reissued a “buy” rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Robert W. Baird reissued a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Jefferies Group LLC reissued a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Finally, Cantor Fitzgerald set a $18.00 target price on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th.
COPYRIGHT VIOLATION NOTICE: “Karyopharm Therapeutics Inc. (KPTI) Receives Consensus Rating of “Buy” from Brokerages” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://ledgergazette.com/2017/11/12/karyopharm-therapeutics-inc-kpti-receives-consensus-rating-of-buy-from-brokerages.html.
Karyopharm Therapeutics (KPTI) traded up $0.14 during midday trading on Monday, hitting $10.91. The company’s stock had a trading volume of 96,500 shares, compared to its average volume of 244,349. Karyopharm Therapeutics has a 52 week low of $7.48 and a 52 week high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities research analysts forecast that Karyopharm Therapeutics will post -2.58 EPS for the current fiscal year.
In other news, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the transaction, the director now directly owns 2,882 shares in the company, valued at approximately $31,702. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Christopher Brett Primiano sold 4,958 shares of the business’s stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total transaction of $55,777.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,653 shares of company stock worth $174,728. 14.71% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of KPTI. Bank of America Corp DE boosted its holdings in Karyopharm Therapeutics by 0.7% in the first quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock worth $592,000 after purchasing an additional 308 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Karyopharm Therapeutics by 8.0% in the second quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock worth $246,000 after purchasing an additional 2,021 shares in the last quarter. American International Group Inc. boosted its holdings in Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after purchasing an additional 2,836 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Karyopharm Therapeutics by 4.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after purchasing an additional 3,762 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in Karyopharm Therapeutics by 10.9% in the first quarter. Swiss National Bank now owns 40,850 shares of the company’s stock worth $525,000 after purchasing an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 59.14% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.